GRAIL-Galleri: why the special treatment?

Lancet. 2024 Feb 3;403(10425):431-432. doi: 10.1016/S0140-6736(23)02830-1. Epub 2024 Jan 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • CD4-Positive T-Lymphocytes*
  • Humans
  • Ubiquitin-Protein Ligases*

Substances

  • Ubiquitin-Protein Ligases